BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32848035)

  • 1. Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8
    Amani MF; Rolig AS; Redmond WL
    J Immunol; 2020 Oct; 205(7):1857-1866. PubMed ID: 32848035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
    J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
    Ruby CE; Redmond WL; Haley D; Weinberg AD
    Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
    Redmond WL; Gough MJ; Weinberg AD
    Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous OX40 stimulation during lymphocytic choriomeningitis virus infection impairs follicular Th cell differentiation and diverts CD4 T cells into the effector lineage by upregulating Blimp-1.
    Boettler T; Choi YS; Salek-Ardakani S; Cheng Y; Moeckel F; Croft M; Crotty S; von Herrath M
    J Immunol; 2013 Nov; 191(10):5026-35. PubMed ID: 24101548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells.
    Mousavi SF; Soroosh P; Takahashi T; Yoshikai Y; Shen H; Lefrançois L; Borst J; Sugamura K; Ishii N
    J Immunol; 2008 Nov; 181(9):5990-6001. PubMed ID: 18941188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition.
    Yu Q; Yue FY; Gu XX; Schwartz H; Kovacs CM; Ostrowski MA
    J Immunol; 2006 Feb; 176(4):2486-95. PubMed ID: 16456009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
    De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
    J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.
    Lei F; Song J; Haque R; Haque M; Xiong X; Fang D; Croft M; Song J
    PLoS One; 2013; 8(8):e70635. PubMed ID: 23936461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
    Hendriks J; Xiao Y; Rossen JW; van der Sluijs KF; Sugamura K; Ishii N; Borst J
    J Immunol; 2005 Aug; 175(3):1665-76. PubMed ID: 16034107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells.
    Soroosh P; Ine S; Sugamura K; Ishii N
    J Immunol; 2007 Oct; 179(8):5014-23. PubMed ID: 17911586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.
    Gramaglia I; Jember A; Pippig SD; Weinberg AD; Killeen N; Croft M
    J Immunol; 2000 Sep; 165(6):3043-50. PubMed ID: 10975814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative signal 3: CD8⁺ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling.
    Sanchez PJ; Kedl RM
    Vaccine; 2012 Feb; 30(6):1154-61. PubMed ID: 22178730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
    Dawicki W; Bertram EM; Sharpe AH; Watts TH
    J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
    Wang HC; Klein JR
    J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet.
    Williams CA; Murray SE; Weinberg AD; Parker DC
    J Immunol; 2007 Jun; 178(12):7694-702. PubMed ID: 17548606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.